A robust derivation of the target population is a key component of the AMNOG process and far more than a formal requirement. Prevalence, incidence, and the transparent derivation of relevant patient numbers are not only a focus of G-BA assessment but are also of central importance for subsequent price negotiations. Methodological weaknesses or uncertainties in epidemiological analysis can therefore have a direct impact on the negotiated reimbursement amount. Especially when standard sources are insufficient or the target population needs to be defined in a more differentiated way, claims data analyses and real-world evidence are becoming increasingly important. 

In this webinar, our experts will show how epidemiological derivations in the AMNOG dossier can be developed in a robust and transparent manner, and what contribution claims data analyses and the Health Research Data Center (FDZ Gesundheit) can make. Using practical case examples from the AMNOG context, we will illustrate how epidemiological requirements, methodological rigor, and a dossier-ready line of argument can be effectively combined. Please note, this webinar will be held in German.

Key Topics

• Epidemiology as a strategic lever in the AMNOG process  
• Limitations of traditional epidemiological data sources  
• How to use claims data analyses effectively  
• FDZ analyses as a new data source: opportunities and challenges

Speakers

Dr. Bastian Gaus, Senior Market Access Consultant, co.value – a Cytel Brand  

Fränce Hardtstock, Director, Real World Evidence, Cytel